SCHEMBL3459044

SCHEMBL3459044

CON(C)C(=O)c1cc(F)c(F)c(F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.48
CES1 P23141 3/20 0.48
MLYCD O95822 1/20 0.46
GPBAR1 Q8TDU6 1/20 0.38
LMNA P02545 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
TRPM8 Q7Z2W7 2/20 0.36
MAOB P27338 1/20 0.35
SLC6A3 Q01959 1/20 0.33
TUBB1 Q9H4B7 2/20 0.33
ALOX5 P09917 1/20 0.33
NFKB1 P19838 1/20 0.33
STAT3 P40763 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26709446 0.88 LMNA (0.42) CES2CES1MLYCDLMNAMAPK1
SCHEMBL24664552 0.85 MLYCD (0.44) CES2CES1MLYCDLMNAMAPK1
SCHEMBL1002689 0.85 MLYCD (0.47) CES2CES1MLYCDGPBAR1LMNA
SCHEMBL3651911 0.82 MLYCD (0.47) CES2CES1MLYCDGPBAR1RAB9A
SCHEMBL20982579 0.82 MLYCD (0.49) CES2CES1MLYCDLMNAMAPK1
SCHEMBL28699664 0.82 MLYCD (0.42) CES2CES1MLYCDLMNAMAPK1
SCHEMBL2014585 0.82 MLYCD (0.40) MLYCDGPBAR1LMNAMAPK1HTT
SCHEMBL2883042 0.81 CES2 (0.52) CES2CES1MLYCDLMNAMAPK1
SCHEMBL22065246 0.81 MLYCD (0.44) MLYCDLMNARAB9ACLK1DYRK1A
SCHEMBL31346688 0.81 ALOX5 (0.51) MLYCDLMNAMAPK1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212277-B1 AMINE LINKED MODULATORS OF Y-SECRETASE JANSSEN PHARMACEUTICA NV (BE) 2016-08-31 EP disclosed
EP-2212277-B1 AMINE LINKED MODULATORS OF Y-SECRETASE JANSSEN PHARMACEUTICA NV (BE) 2016-08-31 EP disclosed
US-20140221664-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (ELECTRON WITHDRAWING GROUPS) GEORGIA TECH RESEARCH CORPORATION (US) 2014-08-07 US disclosed
US-20140221664-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (ELECTRON WITHDRAWING GROUPS) GEORGIA TECH RESEARCH CORPORATION (US) 2014-08-07 US disclosed
US-20140221664-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (ELECTRON WITHDRAWING GROUPS) GEORGIA TECH RESEARCH CORPORATION (US) 2014-08-07 US disclosed
EP-2742024-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (ELECTRON WITHDRAWING GROUPS) Georgia Tech Research Corporation (US) 2014-06-18 EP disclosed
WO-2013023108-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (HETEROARYLENE SPACER MOIETY) GEORGIA TECH RESEARCH CORPORATION (US) 2013-02-14 WO disclosed
WO-2013023106-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (ACYL MOIETIES) GEORGIA TECH RESEARCH CORPORATION (US) 2013-02-14 WO disclosed
WO-2013023109-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (COUPLED TRICYCLIC CORE COMPOUNDS) GEORGIA TECH RESEARCH CORPORATION (US) 2013-02-14 WO disclosed
WO-2013023107-A1 COUPLED HETEROARYL COMPOUNDS VIA REARRANGEMENT OF HALOGENATED HETEROAROMATICS FOLLOWED BY OXIDATIVE COUPLING (ELECTRON WITHDRAWING GROUPS) GEORGIA TECH RESEARCH CORPORATION (US) 2013-02-14 WO disclosed
US-8247610-B2 Amine linked modulators of γ-secretase JANSSEN PHARMACEUTICA N.V. (BE) 2012-08-21 US disclosed
US-8247610-B2 Amine linked modulators of γ-secretase JANSSEN PHARMACEUTICA N.V. (BE) 2012-08-21 US disclosed
WO-2010147234-A1 DIARYLAMIDE-SPIRODIAMINE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-12-23 WO disclosed
EP-2212277-A1 AMINE LINKED MODULATORS OF Y-SECRETASE Janssen Pharmaceutica, N.V. (BE) 2010-08-04 EP disclosed
US-20090105300-A1 AMINE LINKED MODULATORS OF y-SECRETASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 US disclosed
US-20090105300-A1 AMINE LINKED MODULATORS OF y-SECRETASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 US disclosed
US-20090105300-A1 AMINE LINKED MODULATORS OF y-SECRETASE JANSSEN PHARMACEUTICA N.V. (BE) 2009-04-23 US disclosed
WO-2009052350-A1 AMINE LINKED MODULATORS OF Y-SECRETASE JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 WO disclosed
WO-2009052350-A1 AMINE LINKED MODULATORS OF Y-SECRETASE JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 WO disclosed
EP-1031572-A1 PYRIDYLPYRROLE DERIVATIVES Sankyo Company Limited (JP) 2000-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105300-A1 AMINE LINKED MODULATORS OF y-SECRETASE BACE1, BACE2, APP CES2 1239/4885CES1 599/4885MLYCD 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.